Weiss A E, Webster W P, Strike L E, Brinkhous K M
Transfusion. 1976 May-Jun;16(3):209-14. doi: 10.1046/j.1537-2995.1976.16376225490.x.
The effect of EACA (epsilon aminocaproic acid) on the survival of factor VIII (F. VIII, antihemophilic factor, AHF) concentrates after infusion in hemophilic subjects was studied using two F. VIII preparations: an intermediate purity "cryoglobulin" and a high purity glycine-precipitated concentrate. In vivo recoveries of F. VIII with both concentrates were found to be close to the values predicted on the basis of concentrate potencies assayed prior to infusion, but not if the labeled potency was used in the calculation. Control studies showed similar first and second phase half-life times and half-disappearance times when the two F. VIII preparations were infused, and both preparations were found to follow a biphasic disappearance curve. The biological half-life (second phase rate of disappearance) was 12 to 13 hours. The administration of EACA in conjunction with the F. VIII concentrates did not prolong the half-life times (first or second phase) or the half-disappearance times.
使用两种VIII因子制剂研究了6-氨基己酸（EACA）对血友病患者输注后VIII因子（F.VIII，抗血友病因子，AHF）浓缩物存活率的影响：一种是中等纯度的“冷球蛋白”，另一种是高纯度甘氨酸沉淀浓缩物。发现两种浓缩物的VIII因子体内回收率均接近输注前测定的浓缩物效价所预测的值，但如果在计算中使用标记效价则不然。对照研究表明，输注两种VIII因子制剂时，其第一相和第二相半衰期以及半消失时间相似，且两种制剂均呈现双相消失曲线。生物学半衰期（第二相消失速率）为12至13小时。EACA与VIII因子浓缩物联合使用并未延长半衰期（第一相或第二相）或半消失时间。
